Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders

Chem Rev. 2007 Jan;107(1):274-302. doi: 10.1021/cr050263h.

Authors

Ao Zhang¹, John L Neumeyer, Ross J Baldessarini

Affiliation

¹ Bioorganic and Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. [email protected]

PMID: 17212477
DOI: 10.1021/cr050263h

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Dopamine Agonists / chemical synthesis*
Dopamine Agonists / chemistry
Dopamine Agonists / therapeutic use
Dopamine Antagonists / chemical synthesis*
Dopamine Antagonists / chemistry
Dopamine Antagonists / therapeutic use
Dopamine D2 Receptor Antagonists
Humans
Mental Disorders / drug therapy
Molecular Structure
Nervous System Diseases / drug therapy
Receptors, Dopamine D1 / agonists
Receptors, Dopamine D1 / antagonists & inhibitors
Receptors, Dopamine D2 / agonists

Substances

Dopamine Agonists
Dopamine Antagonists
Dopamine D2 Receptor Antagonists
Receptors, Dopamine D1
Receptors, Dopamine D2